Multimarker approach to risk stratification for long-term mortality in patients on chronic hemodialysis

Circulation Journal

Volumn 79, Issue 3, 2015, Pages 656-663

  Ishii, Junnichi ^a   Takahashi, Hiroshi ^a   Kitagawa, Fumihiko ^a   Kuno, Atsuhiro ^a   Okuyama, Ryuunosuke ^a   Kawai, Hideki ^a   Muramatsu, Takashi ^a   Naruse, Hiroyuki ^a   Motoyama, Sadako ^a   Matsui, Shigeru ^a   Hasegawa, Midori ^a   Aoyama, Toru ^b   Kamoi, Daisuke ^b   Kasuga, Hirotake ^b   Izawa, Hideo ^c   Ozaki, Yukio ^a   Yuzawa, Yukio ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kaikoukai Nagoya Kyoritsu Hospital   (Japan)

^c FUJITA HEALTH UNIVERSITY BANTANE HOSPITAL   (Japan)

Author keywords

B type natriuretic peptide; Cardiac troponin T; Hemodialysis; High sensitivity C reactive protein; Mortality

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; TROPONIN T; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; METABOLISM; RENAL REPLACEMENT THERAPY; SURVIVAL RATE;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; SURVIVAL RATE; TROPONIN T;

EID: 84923457678     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0915     Document Type: Article

References (40)

1. Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, et al. Overview of regular dialysis treatment in Japan (as of 31 December 2008). Ther Apher Dial 2010; 14: 505–540.
2. Ortiz A, Massy ZA, Fliser D, Lindholm B, Wiecek A, Martinez- Castelao A, et al. Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol 2011; 8: 141–150.
3. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358–362.
4. Ishii J, Nomura M, Okuma T, Minagawa T, Naruse H, Mori Y, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta 2001; 312: 69–79.
5. Mallamaci F, Zoccali C, Parlongo S, Tripepi G, Benedetto FA, Cutrupi S, et al. Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2002; 40: 68–75.
6. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941–2945.
7. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, et al; Creed Investigators. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508–1515.
8. Wang AY, Lam CW, Yu CM, Chan IH, Zhang Y, Lui SF, et al. Nterminal pro-brain natriuretic peptide: An independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007; 18: 321–330.
9. Winkler K, Wanner C, Drechsler C, Lilienthal J, Marz W, Krane V; German Diabetes and Dialysis Study Investigators. Change in Nterminal- pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008; 29: 2092–2099.
10. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int 2001; 59: 407–414.
11. Takahashi H, Ishii H, Aoyama T, Kamoi D, Kasuga H, Ito Y, et al. Association of cardiac valvular calcifications and C-reactive protein with cardiovascular mortality in incident hemodialysis patients: A Japanese cohort study. Am J Kidney Dis 2013; 61: 254–261.
12. Khan NA, Hemmelgarn BR, Tonelli M, Thompson CR, Levin A. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: A meta-analysis. Circulation 2005; 112: 3088–3096.
13. Needham DM, Shufelt KA, Tomlinson G, Scholey JW, Newton GE. Troponin I and T levels in renal failure patients without acute coronary syndrome: A systematic review of the literature. Can J Cardiol 2004; 20: 1212–1218.
14. Cheng YJ, Yao FJ, Liu LJ, Tang K, Lin XX, Li WJ, et al. B-type natriuretic peptide and prognosis of end-stage renal disease: A metaanalysis. PLoS One 2013; 8: e79302, doi:10.1371/journal.pone.0079302.
15. Bazeley J, Bieber B, Li Y, de Sequera P, Combe C, Yamamoto H, et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol 2011; 6: 2452–2461.
16. Wang AY, Wai-Kei Lam C. The diagnostic utility of cardiac biomarkers in dialysis patients. Semin Dial 2012; 25: 388–396.
17. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363–369.
18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 1988; 44: 837–845.
19. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172.
20. Defilippi C, Wasserman S, Rosanio S, Tiblier E, Sperger H, Tocchi M, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290: 353–359.
21. Satyan S, Light RP, Agarwal R. Relationships of N-terminal pro-Bnatriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 50: 1009–1019.
22. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int 2005; 67: 2330–2337.
23. Wang AY, Lam CW, Wang M, Chan IH, Goggins WB, Yu CM, et al. Prognostic value of cardiac troponin T is independent of inflammation, residual renal function, and cardiac hypertrophy and dysfunction in peritoneal dialysis patients. Clin Chem 2007; 53: 882–889.
24. Apple FS, Murakami MM, Pearce LA, Herzog CA. Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 2004; 50: 2279–2285.
25. Bargnoux AS, Morena M, Jaussent I, Maurice F, Chalabi L, Leray- Moragues H, et al. A combined index of cardiac biomarkers as a risk factor for early cardiovascular mortality in hemodialysis patients. Clin Chem Lab Med 2013; 51: 1865–1874.
26. Hallen J, Madsen L, Ladefoged S, Fagerland MW, Serebruany VL, Agewall S, et al. Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. Scand J Urol Nephrol 2011; 45: 151–158.
27. Geerse DA, van Berkel M, Vogels S, Kooman JP, Konings CJ, Scharnhorst V. Moderate elevations of high-sensitivity cardiac troponin I and B-type natriuretic peptide in chronic hemodialysis patients are associated with mortality. Clin Chem Lab Med 2013; 51: 1321–1328.
28. Hickman PE, McGill DA, Talaulikar G, Hiremagalur B, Bromley J, Rahman A, et al. Prognostic efficacy of cardiac biomarkers for mortality in dialysis patients. Intern Med J 2009; 39: 812–818.
29. McGill D, Talaulikar G, Potter JM, Koerbin G, Hickman PE. Over time, high-sensitivity TnT replaces NT-proBNP as the most powerful predictor of death in patients with dialysis-dependent chronic renal failure. Clin Chim Acta 2010; 411: 936–939.
30. London GM. Cardiovascular disease in chronic renal failure: Pathophysiologic aspects. Semin Dial 2003; 16: 85–94.
31. Damman P, Beijk MA, Kuijt WJ, Verouden NJ, van Geloven N, Henriques JP, et al. Multiple biomarkers at admission significantly improve the prediction of mortality in patients undergoing primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 2011; 57: 29–36.
32. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al; Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J 2012; 33: 2252–2257.
33. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58: 54–61.
34. Mueller M, Vafaie M, Biener M, Giannitsis E, Katus HA. Cardiac troponin T: From diagnosis of myocardial infarction to cardiovascular risk prediction. Circ J 2013; 77: 1653–1661.
35. Held PJ, Brunner F, Odaka M, Garcia JR, Port FK, Gaylin DS. Fiveyear survival for end-stage renal disease patients in the United States, Europe, and Japan, 1982 to 1987. Am J Kidney Dis 1990; 15: 451–457.
36. Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, et al. Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol 2007; 165: 617–624.
37. Kumada Y, Ishii H, Aoyama T, Kamoi D, Kawamura Y, Sakakibara T, et al. Long-term clinical outcome after surgical or percutaneous coronary revascularization in hemodialysis patients. Circ J 2014; 78: 986–992.
38. Coe CL, Love GD, Karasawa M, Kawakami N, Kitayama S, Markus HR, et al. Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. Brain Behav Immun 2011; 25: 494–502.
39. Oldroyd JC, Heald A, Bansal N, Vyas A, Siddals K, Gibson M, et al. Inflammatory markers and growth in South Asian and European origin infants in Britain: The Manchester Children’s Growth and Vascular Health Study. Atherosclerosis 2009; 207: 227–231.
40. K⁄ DOQI Workgroup. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45(Suppl 3): S1–S153.